Translational research is the process whereby ideas and discoveries from emerging research projects are translated into products of therapeutic value for human patient benefit. Where discoveries in “basic science” improve our understanding of a disease, the aim of translational research is to move basic science into practice and to improve human health through the development of drugs, therapies, techniques and medical devices.
Applications may consider:
- Innovation in therapeutic discovery and development
- Addressing an unmet need in cancer healthcare, or offer a new solution to a problem
- Translation of fundamental discoveries into improvements in cancer outcomes
- Translate basic science discoveries quickly and effectively into cancer practice eg. product, technology or intervention
- Developing a product, technology or intervention which can be moved towards application in a patient setting
Applications for this funding round are open to researchers across the United Kingdom. In making their applications, researchers should consider the relevance of their application to the people of the North West of England and North Wales. This could mean overall incidence or that the particular cancer type if more common or associated with poor outcomes within the region.
Applicants may be from academic, healthcare, social care or other sectors. We encourage collaborations between institutions and NHS organisations and encourage collaborative applications within our regional footprint.
The Translational Research call accepts grant proposals of up to three years, with funding of up to £275,000. Researchers should be mindful of the current resources available to NWCR. All applications will be equally considered, regardless of whether funding is requested at the higher or lower end of the funding budget.
All applications will undergo rigorous external peer and scientific review. Panel members will be made available to view once confirmed.
This funding round will close at 5pm on 11th October 2021.
Applications must be submitted in line with call guidance and appendix A if required.